(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of 27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is forecast to beat the US market's average forecast revenue growth rate of 7.51%.
Sarepta Therapeutics's revenue in 2023 is $1,104,982,000.On average, 8 Wall Street analysts forecast SRPT's revenue for 2023 to be $113,667,543,070, with the lowest SRPT revenue forecast at $110,925,128,569, and the highest SRPT revenue forecast at $117,111,089,944. On average, 8 Wall Street analysts forecast SRPT's revenue for 2024 to be $160,647,060,455, with the lowest SRPT revenue forecast at $132,836,287,020, and the highest SRPT revenue forecast at $193,923,205,180.
In 2025, SRPT is forecast to generate $212,665,750,452 in revenue, with the lowest revenue forecast at $141,678,319,308 and the highest revenue forecast at $276,754,113,871.